A Phase I Trial Combining IDEC-Y2B8 [ibritumomab tiuxetan Y-90] And High-Dose BEAM Chemotherapy [carmustine + etoposide + cytarabine + melphalan] With Hematopoietic Progenitor Cell Transplant In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Carmustine; Cytarabine; Etoposide; Filgrastim; Ibritumomab tiuxetan; Melphalan; Rituximab
- Indications B-cell lymphoma
- Focus Adverse reactions
- 01 Jun 2012 Biomarkers information updated
- 31 May 2012 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 01 Jul 2011 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.